This is a website for healthcare professionals.
AVISE CTD
Building the Foundation for a Diagnosis
AVISE CTD is a comprehensive offering that enables clinicians to more effectively diagnose complex autoimmune conditions such as lupus, rheumatoid arthritis and Sjogren's disease earlier and with greater accuracy.
AVISE CTD delivers comprehensive, actionable results
With over 30 biomarkers carefully selected by rheumatologists for their clinical and diagnostic relevance, AVISE CTD helps improve diagnostic accuracy, reducing uncertainty and aiding in earlier diagnosis.
The T Cell and new RA biomarkers are not orderable at this time. More details about their official launch date will be available soon.
AVISE is proven to enhance patient care and provider confidence
Exagen is a leading autoimmune diagnostics company with extensive peer reviewed literature supporting the clinical utility of its proprietary technology, demonstrating actional results that support treatment decisions.
References:
- Erythrocyte-bound C4d in combination with complement and autoantibody status for the monitoring of SLE.
- Cell-bound complement activation products in SLE. Ramsey-Goldman R, et al. Lupus Science and Medicine. 2017.
- Cell-bound complement activation products in systemic lupus erythematosus: comparison with anti-double-stranded DNA and standard complement measurements. Putterman C. et al. Lupus Science and Medicine. 2014.
- Systemic lupus erythematosus and primary fibromyalgia can be distinguished by testing for cell-bound complement activation products. Wallace D. et al. Lupus Science & Medicine. 2016.
- The AVISE Lupus Test and Cell-bound Complement Activation Products Aid the Diagnosis of Systemic Lupus Erythematosus. Mossell J. et al. The Open Rheumatology Journal. 2016.